hit counter
Arcturus Therapeutics Ltd. (ARCT) Stock News Sentiment & Price - Sentifly
ARCT - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Arcturus Therapeutics Ltd. (ARCT)

USA
Biotechnology
NASDAQ
ARCT Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ARCT Latest news
Seeking Alpha
Neutral
Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q3 2021 Results - Earnings Call Transcript
2021-11-08 19:50

Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q3 2021 Results - Earnings Call Transcript

Zacks Investment Research
Negative
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue Estimates
2021-11-08 19:09

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -46.43% and -90.87%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Business Wire
Neutral
Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress
2021-11-08 16:00

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress

Zacks Investment Research
Negative
Earnings Preview: Arcturus Therapeutics (ARCT) Q3 Earnings Expected to Decline
2021-11-01 16:06

Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire
Neutral
Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021
2021-10-25 16:00

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the third quarter ended September 30, 2021 after the market close on Monday November 8, and will also host a conference call and webcast at

Business Wire
Neutral
Arcturus Therapeutics Announces Leadership Appointments
2021-10-21 08:00

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Announces Leadership Appointments

Business Wire
Neutral
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2021-10-20 20:00

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

The Motley Fool
Neutral
Cathie Wood Just Bought Shares of This Vaccine Underdog. Should You?
2021-10-15 06:00

The company disappointed last year, but things may be turning around.

Business Wire
Neutral
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
2021-10-12 08:00

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Vietnam Ministry of Health has approved initiation of the Phase 3b part of the placebo-controlled, observer-blind Phase 1/2/3 clinical trial of ARCT-154 self-replicating RNA vacc

The Motley Fool
Neutral
After COVID-19, Could This Be the Next Billion-Dollar Vaccine Market?
2021-10-04 06:00

Three healthcare giants are vying for the prize.

Loading more news...